相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
I. V. Fedorenko et al.
ONCOGENE (2016)
BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth
Tao Wang et al.
CLINICAL CANCER RESEARCH (2015)
Twist1 Is a Key Regulator of Cancer-Associated Fibroblasts
Keun-Woo Lee et al.
CANCER RESEARCH (2015)
Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor
Curtis H. Kugel et al.
CANCER RESEARCH (2014)
Resistance to RAF Inhibitors Revisited
Edward Hartsough et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant-Expressing Melanoma
Edward J. Hartsough et al.
MOLECULAR CANCER RESEARCH (2014)
Identification of mTORC2 as a Necessary Component of HRG/ErbB2-Dependent Cellular Transformation
Miao-chong J. Lin et al.
MOLECULAR CANCER RESEARCH (2014)
Adaptive resistance to RAF inhibitors in melanoma
Curtis H. Kugel et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
Inhibition of mutant BRAF splice variant signaling by next- generation, selective RAF inhibitors
Kevin J. Basile et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
Chong Sun et al.
CELL REPORTS (2014)
Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers
Joan T. Garrett et al.
CANCER RESEARCH (2013)
In Vivo MAPK Reporting Reveals the Heterogeneity in Tumoral Selection of Resistance to RAF Inhibitors
Kevin J. Basile et al.
CANCER RESEARCH (2013)
An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
Andrew P. Garner et al.
CANCER RESEARCH (2013)
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Ethan V. Abel et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Stat3-Targeted Therapies Overcome the Acquired Resistance to Vemurafenib in Melanomas
Fang Liu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival
Keman Zhang et al.
PIGMENT CELL & MELANOMA RESEARCH (2013)
Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells
Kaitlyn Le et al.
PIGMENT CELL & MELANOMA RESEARCH (2013)
Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
Maria R. Girotti et al.
CANCER DISCOVERY (2013)
Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Cristina Montero-Conde et al.
CANCER DISCOVERY (2013)
Carcinoma-Associated Fibroblasts Are a Promising Therapeutic Target
Shinsaku Togo et al.
Cancers (2013)
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
Piro Lito et al.
CANCER CELL (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson et al.
NATURE (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis
M. Lindzen et al.
ONCOGENE (2012)
A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth
K. Zhang et al.
ONCOGENE (2012)
Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma
J. S. Liles et al.
BRITISH JOURNAL OF CANCER (2011)
Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options
Jessie Villanueva et al.
CANCER RESEARCH (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells
F. M. Kaplan et al.
ONCOGENE (2011)
An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells
Qing Sheng et al.
CANCER CELL (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
The fibroblast-derived paracrine factor neuregulin-1 has a novel role in regulating the constitutive color and melanocyte function in human skin
Wonseon Choi et al.
JOURNAL OF CELL SCIENCE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
Ruth Halaban et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
NRG1/ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation
Kristina Buac et al.
PIGMENT CELL & MELANOMA RESEARCH (2009)
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Jose Baselga et al.
NATURE REVIEWS CANCER (2009)
HER3 is a determinant for poor prognosis in melanoma
Markus Reschke et al.
CLINICAL CANCER RESEARCH (2008)
Neuregulin 1 in neural development, synaptic plasticity and schizophrenia
Lin Mei et al.
NATURE REVIEWS NEUROSCIENCE (2008)
Friends or foes - Bipolar effects of the tumour stroma in cancer
MM Mueller et al.
NATURE REVIEWS CANCER (2004)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
分享论文
